Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 54-week, Phase II, Multi-center, Open-label Extension Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1B Monoclonal Antibody) in Patients With Rheumatoid Arthritis

NCT00554606 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00554606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00554606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 54-week, Phase II, Multi-center, Open-label Extension Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1B Monoclonal Antibody) in Patients With Rheumatoid Arthritis
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Completed
Start date
October 11, 2007
Completion date
August 13, 2009
Enrollment
115 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis